Skip to main content
OpenTrials
Completed

NCT Number: NCT02177305

Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers

Safety and tolerability after ocular administration

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

21 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males
  • Age range from 21 to 50 years
  • Within ± 20% of normal weight (Broca-Index)
  • Written informed consent given

Exclusion criteria

  • Results of the medical examinations or laboratory tests are judged by the clinical investigator to differ significantly from normal clinical values
  • Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Volunteers with disease of the central nervous system (such as epilepsy) or with psychiatric disorders
  • Volunteers with known history of orthostatic hypotension, fainting spells or blackouts
  • Volunteers with chronic or relevant acute infections
  • Volunteers with history of allergy/ hypersensitivity (including drug allergy)
  • Volunteers with known eye diseases (incl. glaucoma), with hyperopia (> 3 diopters) or with contact lenses
  • Volunteers with intraocular pressure > 22 mmHg
  • Volunteers with predisposition to narrow-angle glaucoma
  • Volunteers with disturbed micturition
  • Volunteers who have taken a drug with a long half-life (≥ 24 hours) within ten half-lives of the respective drug before enrolment in the study
  • Volunteers who received any other drugs which might influence the results of the trial during the week previous the start of the study
  • Volunteers who have participated in another study with an investigational drug within the last two months preceding this study
  • Volunteers who smoke (> 10 cigarettes or 3 cigars or 3 pipes/day)
  • Volunteers who are not able to refrain from smoking on study day
  • Volunteers who drink more than 40 g of alcohol per day
  • Volunteers who are dependent on drugs
  • Volunteers who have donated blood (≥ 100 ml) within the last four weeks
  • Volunteers who participated in excessive physical activities (e.g. competitive sports) within the last week before the study

Treatment and study plan

0.02 mcg tiotropium solution

Drug

0.04 mcg tiotropium solution

Drug

0.08 mcg tiotropium solution

Drug

0.16 mcg tiotropium solution

Drug

0.28 mcg tiotropium solution

Drug

0.40 mcg tiotropium solution

Drug

Placebo solution

Drug

Primary outcomes

  1. Change in pupil diameter

    Time frame: baseline, after 24 hours

  2. Change in pupillary reflex

    Time frame: baseline, after 24 hours

  3. Change in intraocular pressure

    Time frame: baseline, after 24 hours

  4. Change in accommodation

    Time frame: baseline, after 24 hours

Secondary outcomes

  1. Change from baseline in blood pressure

    Time frame: on Day 1 before and 24 hours after treatment and within 8 days after treatment day

  2. Change from baseline in pulse rate

    Time frame: on Day 1 before and 24 hours after treatment and within 8 days after treatment day

  3. Change in 12-lead ECG

    Time frame: on Day 1 before and 24 hours after treatment and within 8 days after treatment day

  4. Changes from baseline in standard laboratory examinations

    Time frame: Baseline and within 8 days after treatment day

  5. Occurrence of Adverse Events

    Time frame: until 8 days after treatment day

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Single Increasing Dose Tolerance Study After Ocular Administration of Tiotropium (Single Doses: 0.02 - 0.4 mcg) in Healthy Male Volunteers (Randomised, Placebo-controlled, Double-blind, Parallel Groups).

Important dates

Study start
1998
Primary completion
1998
First posted
Jun 27, 2014
Registry last updated
Jun 27, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.